New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
16:19 EDTFLXNFlexion signs worldwide exclusive license with Southwest Research Institute
Flexion Therapeutics announced that it has executed an exclusive worldwide licensing agreement with the Southwest Research Institute, or SwRI, to utilize proprietary microsphere manufacturing technologies for production of Flexion's sustained-release drug candidates, including leading candidate FX006. The SwRI technologies employ a uniquely controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of phase 3 clinical trial material and commercial supply. Flexion has successfully used this technology to produce clinical trial microsphere product for its lead drug candidate FX006, which has been tested in more than 200 patients.
News For FLXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
09:39 EDTFLXNFlexion FDA letter a 'best case' scenario, says Summer Street
Summer Street learned that Flexion recently received its clinical hold letter from the FDA, and after speaking with management, believes the letter confirms a "best case" scenario for the company. The firm says the FDA is requiring Flexion to determine that the infection in the trial was not related to FX006, rather than the more challenging task of determining the ultimate root cause of the infection. It reiterates a Buy rating on the stock with a $28 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use